<![CDATA[Daratumumab - Subcutaneous video]]>Instructional video for preparation and administration of the coformulated subcutaneous formulation of daratumumab, aslo known as DARA-SC

]]>https://dev.proinvestor.com/forum/topic/440251/daratumumab-subcutaneous-videoRSS for NodeWed, 15 Jul 2026 08:21:19 GMTSun, 29 Sep 2019 06:14:41 GMT60<![CDATA[Reply to Daratumumab - Subcutaneous video on Tue, 01 Oct 2019 12:37:56 GMT]]>Genmab/Dara sub. - "Scott White Yes. From a commercial perspective, we believe the subcu formulation is something that's going to open up a lot of doors for us, especially in earlier lines of therapy. If you look at DARZALEX, its utilization to market, about 50% is being used in hospitals, half is being used in the community setting. With community doctors, there's a capacity issue, especially with long infusion times, especially when you're looking at line 1 and line 2 patients".

Fra Genmabchatten d. 1. oktober 2019 med tak til Solsen

]]>https://dev.proinvestor.com/forum/post/9453433https://dev.proinvestor.com/forum/post/9453433Tue, 01 Oct 2019 12:37:56 GMT